Phase 4 N=180 Evaluation of Boostrix™10 Years After Previous Booster Vaccination
Acellular Pertussis · Tetanus · Diphtheria
Primary: Number of Seroprotected Subjects Against Diphtheria and Tetanus — 53; 59; 65; 54 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=129 Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma
Lymphoma
Primary: Event-free Survival (EFS) — 74; 79 percentage of participants
N/A N=12 Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis
Atopic Keratoconjunctivitis
Primary: Ocular Symptoms and Signs Total Composite Score — 29.1; 4.7 units on a scale — p=0.002
N/A N=40 Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)
Malignant Neoplasm
Primary: Overall CR(Complete Response)After the First Course of HEC, Defined as no Emesis and no Use of Rescue Medication — 65; 40 percentage of patients
N/A N=120 Effectiveness of Cervical Facet Joint Nerve Blocks
Neck Pain
Primary: Numeric Rating Scale (NRS) — 8.2; 8.2; 3.5; 3.2 units on a scale — p=<0.05
Phase 4 N=871 A Time-motion Study Comparing Self- to Nurse-vaccination With Influenza Vaccine
Influenza · Vaccination Site Reactions (HT)
Primary: Time to Administer Influenza Vaccine (in Seconds) — 90.0; 182.0; 62.6 seconds
N/A N=65 Optimize RV Follow-up Selective Site Pacing Clinical Trial
Cardiac Pacing · Right Ventricular Pacing · Left Ventricular Ejection Fraction
Primary: Difference in Mean Left Ventricular Ejection Fraction (LVEF) Between RV Pacing Sites at 24 Month — 48.3; 51.2 percentage of LVEF — p=0.2352
Phase 2 N=35 Inhalation of Corticosteroids in Smoking and Non-smoking Asthmatics.
Asthma
Primary: Late Asthmatic Response (LAR) - Smokers: Absolute Change From Saline in Minimum Forced Expiratory Volume in One Second (FEV1) Between 4-10 Hours (Hrs) After Allergen…
Phase 2 N=12 A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes
Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
Primary: PK Phase: Area-under-the Concentration-time Curve (AUC0-24) for Lenalidomide — 817 ng*h/mL
N/A N=16 Acute Effects of Coffee on Appetite and Inflammation Markers, Glucose Metabolism and Energy Intake
Health
Primary: Ghrelin Total Area Under the Curve — 2669; 2593; 2672 ug*h/mL
Phase 3 N=1,102 E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Metastatic Breast Cancer
Primary: Overall Survival (OS) — 484; 440 days
Phase 2 N=70 A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Liver Transplant Patients
Liver Transplantation
Primary: Area Under the Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) for Tacrolimus — 215.6; 184.0; 202.4; 187.9 ng*hr/mL
N/A N=43 Vitamin D Supplementation to Obese Chinese Males
Obesity · Insulin Resistance
Primary: Plasma 25-hydroxy Vitamin D (25(OH)D) Level (Nmol/L) — 116.7; 181.3; 46.1; 52.8 nmol/L
Phase 2 N=82 Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis
Atopic Dermatitis
Primary: Comparison of Anti-YF Antibody Levels by Measurement of Log10 Neutralization Index (LNI): YFV-17D TC- (AD) Participants Compared to YFV-17D TC- (Non-AD) Participants…
Phase 4 N=228 Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)
Attention Deficit Disorder With Hyperactivity
Primary: Dichotomized Clinical Global Impression-Effectiveness (CGI-E) Scale — 7.0; 5.0; 6.0; 6.0 Units on a scale